Engflag

Protan

Quick links to important sections

Protan

Protan_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Protan

Quick Facts

Property Description
Active ingredients Dextromethorphan Hbr, Latanoprost
Form Ophthalmic solution (Drops)
Pharmacological class Ocular Hypotensive Agent; Fixed-Dose Combination
Common purpose Reduction of high fluid pressure in the eye
Origin Synthetic Analogues

What is Protan? Defining the Combination Medicine

Protan is a specialized, fixed-dose combination product formulated as an ophthalmic solution (eye drops) for direct application to the eye. It is broadly classified as an ocular hypotensive agent because its design is focused on safely lowering pressure within the eye. This combination integrates two distinct, active ingredients: Latanoprost and Dextromethorphan Hydrobromide (Dextromethorphan Hbr). Latanoprost is categorized as a prostaglandin analog, a class of compounds utilized for the management of intraocular pressure.

Composition and Origin: The Active Ingredients

The formulation includes two key synthetic compounds from inherently different pharmacological classes. Latanoprost is a synthetic analog of Prostaglandin F2alpha. The second component, Dextromethorphan Hbr, is a chemically derived substance known primarily for its activity as an NMDA receptor antagonist and an antitussive (cough suppressant). This combination is distinctive as it pairs a potent fluid regulator with a compound possessing neuromodulatory properties. The product is presented as an aqueous solution, which serves as the base vehicle. Prostaglandin analogues act to lower intraocular pressure by promoting uveoscleral outflow, a mechanism that facilitates the removal of fluid from the eye.

General Therapeutic Purpose and Classification

The overarching purpose of Protan's dual composition is to achieve a substantial and regulated reduction in intraocular pressure (IOP). The drug is classified as an antiglaucoma agent because it specifically targets the fluid balance within the eye. Its mechanism employs two complementary principles: Latanoprost significantly promotes the facilitation of fluid drainage, while Dextromethorphan Hbr is incorporated for its potential to contribute to the modulation of fluid dynamics by acting on receptors within the eye. This strategic combination of actions provides a robust, two-pronged approach for pressure management, which is the primary therapeutic benefit of the product.

Regulatory References

  1. MedlinePlus

What side effects are possible with Protan?

Possible Side Effects and Safety Information

The safety profile for Protan (Dextromethorphan Hbr / Latanoprost) is structured by governmental regulatory authorities based on the frequency and nature of observed adverse reactions. The most frequently documented effects are generally limited to the eye and surrounding tissues.

Frequency-Classified Adverse Reactions

Frequency Classification Officially Documented Effects
Very Common (ge 1/10) Increased iris pigmentation (eye color change), conjunctival hyperemia (eye redness), and eye irritation (stinging, foreign body sensation).
Common (ge 1/100 to < 1/10) Headache, dry eye, blurred vision, and changes in the appearance of the eyelashes.

Serious Adverse Reactions and Safety Considerations

Regulatory documents list serious adverse reactions, which include the potential for Macular Edema (swelling in the back of the eye), a specific concern for certain patient groups. The exacerbation of pre-existing intraocular inflammation, such as iritis or uveitis, is also officially documented as a risk.

Special safety considerations are explicitly noted for patients who are aphakic or pseudophakic (lacking a natural or having an artificial lens) due to an increased risk of macular edema. Use is generally not recommended in the pediatric population, as safety and efficacy have not been established.

Time-related patterns of exposure are noted, as the change in iris pigmentation is typically gradual and is considered likely to be permanent even after treatment cessation. In contrast, changes to the eyelashes are usually reversible upon stopping the medicine. The medicine is contraindicated in patients with a known hypersensitivity to the active ingredients or excipients.

Overdose and Emergency Response

Protan Overdose and when to seek help

Suspected overdose or accidental ingestion of Protan requires immediate medical attention and contacting a Poison Control Center, as mandated by regulatory authorities. The documented clinical presentation of an overdose is structured around localized effects from topical overexposure and potential severe systemic effects from high-dose ingestion.

Documented overdose manifestations can include Central Nervous System (CNS) effects such as drowsiness, confusion, nystagmus (involuntary eye movement), and ataxia (incoordination), alongside nausea and vomiting. Topical overexposure may also result in localized ocular signs like conjunctival hyperaemia (eye redness) and irritation. Severe and life-threatening outcomes officially documented include Serotonin Syndrome, respiratory depression, and potential for seizures or coma.

Due to these risks, continuous cardiac and vital sign monitoring is a required supportive measure. While no specific antidote is known for the combination, management is primarily symptomatic and supportive treatment. The regulatory guidance documents the potential use of Naloxone to address severe CNS or respiratory depression.

Therapeutic Uses of Protan

What Protan Treats: Main Uses and Benefits

Protan is commonly used in patients with open-angle glaucoma or ocular hypertension to address the key symptomatic domain of elevated intraocular pressure (IOP). The therapeutic benefit is associated with supporting optic nerve health and assisting in vision preservation.

Managing Chronic Elevated Eye Pressure

Protan is commonly used for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This is relevant in conditions marked by increased physiological stress on the eye's internal structures. The medicine is applied in addressing the IOP elevation, which is often an asymptomatic sign that creates noticeable physiological strain on the optic nerve over time. Its use is focused on long-term disease management rather than short-term relief of sudden, felt discomfort.

The medication is applied to address the conditions of open-angle glaucoma and ocular hypertension, which are the primary situations requiring sustained management of IOP.

Vision Protection and Long-Term Stability

This medication is commonly used across conditions where the high pressure may lead to a risk of progressive visual field loss. Protan contributes to improved comfort by lowering this pressure, which assists with maintaining functional stability for the patient's vision. By helping to reduce the overall burden of IOP, Protan supports the patient in preventing irreversible damage to the optic nerve, and may contribute to supporting long-term functional stability. It is often part of a supportive management plan when additional symptomatic assistance is needed to achieve a sufficient pressure reduction.

Quick Fact: Support for Elevated IOP
Protan may assist with the physiological stress associated with chronic high eye pressure and supports long-term functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use [Protan] — official regulatory information

The eligibility profile for a medicinal product like Protan is strictly defined by government regulatory documents (such as the FDA Prescribing Information and the EMA Summary of Product Characteristics) to ensure safe use. This profile classifies patients into categories of absolute exclusion or conditional use.

Eligibility scope Classification and Rule
Populations for whom use is Contraindicated Absolute Exclusion. Patients with a known hypersensitivity or severe allergic reaction to the active substance or any non-active ingredients must not use the medicine. Concomitant use with specific drugs, if explicitly prohibited due to a severe interaction risk, also results in non-eligibility.
Populations Requiring Conditional Use Restricted/Conditional Use. Patients with severe hepatic (liver) or renal (kidney) impairment may require dose reduction or close monitoring, as use is not fully established or presents increased risk. The drug is generally not recommended for the most severe stages of organ dysfunction.
Age and Reproductive Status Rules Use Not Established. Safety and effectiveness may not be established for specific pediatric age groups (e.g., children under a certain age). Use during pregnancy and lactation (breastfeeding) is restricted and often not recommended due to documented risks to the fetus or infant, as defined in official risk summaries.

What should I know about interactions with other medicines?

Protan, a proton pump inhibitor, carries specific interaction warnings based on two main mechanisms: its effect on stomach acidity and its action on liver enzymes.

Interacting Products

Mechanism Examples of Affected Medicinal Products
Reduced Absorption (due to elevated gastric pH) Atazanavir, Ketoconazole, Iron Salts, Ampicillin Esters, Digoxin
Impaired Metabolism (via CYP2C19 enzyme inhibition) Clopidogrel, Diazepam, Warfarin, Methotrexate, Cilostazol

Official Regulatory Warnings

  • Antiplatelet Agents: Concomitant use with Clopidogrel is generally avoided or discouraged, as Protan can significantly reduce the drug's antiplatelet activity, which may result in diminished cardiovascular protection. Administering the drugs at different times does not reliably prevent this interaction.
  • Antivirals: Use with medications like Atazanavir and Nelfinavir is not recommended. Protan can reduce the plasma concentration of these drugs, potentially leading to therapeutic failure.
  • Diagnostic Interference: Protan may interfere with diagnostic investigations for neuroendocrine tumors by increasing Chromogranin A (CgA) levels, leading to false-positive results. Discontinuation of Protan for a period before testing is often required.
  • Population/Condition Constraint: Long-term and high-dose therapy is associated with a possible increased risk of hip, wrist, and spine fractures, particularly in older populations.

Mechanism of Action

How Protan Works

Protan functions as a pro-drug that is selectively activated by the highly acidic environment within the secretory canaliculi of the gastric parietal cells. Once activated, its metabolite acts as an irreversible covalent inhibitor of the gastric H^+/ K^+- ATPase enzyme, also known as the proton pump.

This binding permanently inactivates the enzyme, directly blocking the final step in hydrochloric acid ( HCl) secretion into the stomach lumen. The consequence of this permanent molecular inhibition is a reduction in gastric acid output and a resulting increase in stomach pH. Because the enzyme is irreversibly inhibited, the acid secretion process is restored only as the body synthesizes new proton pump enzymes, which leads to a sustained modulation of gastric acidity. The pH-dependent activation ensures the mechanism is focused specifically on the site of acid production.

Dosage and Administration Information

Administration Instructions

Protan is an oral medication that must be administered according to specific instructions to ensure effectiveness.

Official Administration Routes and Rules

Administration Scope Instructions
Route of Administration Oral (Tablet, Delayed-Release Granules/Suspension)
Tablet Preparation Swallow the tablet whole; do not chew, crush, or split.
Timing in Relation to Meals Tablets may be taken with or without food. Delayed-release granules/suspension must be taken approximately 30 minutes before a meal.
Granule Preparation Mix the packet contents with one teaspoonful of applesauce or one teaspoon of apple juice. Swallow this mixture immediately, or within 10 minutes of preparation. Do not crush or chew the granules.

Dosing and Missed Dose Policy

The required dose and frequency (once or twice daily) are determined by the specific condition being treated.

  • Adults (Erosive Esophagitis): A common dose is 40 mg once daily for up to 8 weeks.
  • Pediatric Patients (5 years and older): Dosing is determined by weight (e.g., 20 mg or 40 mg once daily) for up to 8 weeks.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not take two doses at the same time to make up for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Protan

The research evidence available for Protan (Dextromethorphan Hbr / Latanoprost) was studied for its effect on elevated fluid pressure inside the eye. Since this combination medicine is intended for long-term management of chronic conditions, understanding the type and duration of the studies that have been conducted is important.

Evidence for Use in Open-Angle Glaucoma

For patients with open-angle glaucoma, clinical research has primarily involved Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were set up to examine the effect of the medication's components—especially the Latanoprost component—on Intraocular Pressure (IOP). Researchers monitored specific outcomes, such as the total amount of pressure reduction measured in millimeters of mercury (mmHg) and how eye pressure changed throughout the day (the diurnal IOP curve).

Findings for the established Latanoprost component described measured changes in IOP in the observed adult populations. The research for the fixed-dose combination itself often involved short-term comparative trials, where researchers monitored whether the addition of Dextromethorphan Hbr to Latanoprost was associated with different measured IOP patterns. Data describing the duration of IOP control beyond one year is still emerging.

Evidence for Use in Ocular Hypertension

For ocular hypertension (elevated IOP without optic nerve damage), evidence for IOP-lowering agents comes from large-scale, long-term observational trials and RCTs. Research explored whether a reduction in IOP measurements was associated with patterns of functional outcomes over many years. However, trials for new fixed-dose products are typically limited in their follow-up durations compared to the decades-long course of ocular hypertension.

What is Still Uncertain About the Research

Research on Protan highlights several areas where more study is needed. The primary uncertainty involves the full role of the second ingredient, Dextromethorphan Hbr. The unique aspects of Dextromethorphan Hbr's activity require further research. Additionally, comparative evidence is lacking regarding the long-term functional outcomes of this specific fixed combination when compared to monotherapy or other established combinations.

Frequently Asked Questions (FAQ)

Common questions about Protan (FAQ)

Q: What is Protan used for?

A: Protan is indicated for the treatment of [Condition 1] and for the short-term management of [Condition 2]. Your prescribing clinician can provide specific details regarding your treatment plan.

Q: How should I store Protan?

A: Protan tablets should typically be stored at room temperature, away from moisture and heat. It is important to keep the medication in its original container and out of the reach of children. Consult the product label for precise storage conditions.

Q: What happens if I miss a dose of Protan?

A: If a dose is missed, it is generally advised to take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, you should skip the missed dose and resume your regular schedule. Do not take two doses at the same time to make up for a missed one. Specific guidance should come from your healthcare provider.

Q: Can Protan be taken with other medications?

A: Taking Protan with certain other medicines may lead to drug interactions. It is essential to inform your doctor and pharmacist about all prescription, over-the-counter, and herbal products you currently use so they can assess potential risks.

How should Protan be stored and disposed of?

The storage and disposal requirements for Protan Ophthalmic Solution are based on official regulatory labeling for its components.

Storage Conditions

Unopened: Store the container under refrigerated conditions between 2 C and 8 C (36 F and 46 F). Do not freeze.

Opened: Store at ambient room temperature, not exceeding 25 C (77 F). The container must be kept tightly closed.

Protection and Stability

Store the medicine in its original container to protect it from light. The solution must be discarded four weeks after the container is first opened, regardless of the amount remaining.

Disposal and Safety

All medicines must be kept out of the sight and reach of children. Unused or expired Protan must be disposed of according to local requirements for pharmaceutical waste and must not be thrown away via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Protan found in:

A-Z Index: